HOSPITAL UNIVERSITARIO RUBER
Departamento
Netherlands Cancer Institute
Amsterda, HolandaPublicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (9)
2024
-
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76
2023
-
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases
Melanoma research, Vol. 33, Núm. 2, pp. 155-158
2021
-
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study
Frontiers in Medicine, Vol. 8
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2019
-
Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
Genome Medicine, Vol. 11, Núm. 1
-
POSEIDON trial phase 1B results: Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients
Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6598-6605
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210